Altimmune, Inc.

Today, we announced the completion of our End-of-Phase 2 meeting with the U.S. FDA and agreement on the design of a Phase 3 registrational program for #pemvidutide in the treatment of #obesity.    This milestone is a critical step as we continue to advance pemvidutide for #obesity and #metabolic diseases. Learn more in the full release: https://lnkd.in/gjfDTxjr

Next week, our Chief Executive Officer, Dr. Vipin Garg, and Chief Medical Officer, M. Scott Harris, will participate in #firesidechats at the Guggenheim Inaugural Healthcare Innovation Conference in Boston and the UBS Global Healthcare Conference in Rancho Palos Verdes. Don’t miss this opportunity to learn more about our lead candidate #pemvidutide, a #GLP1/#Glucagon dual receptor agonist for the treatment of #obesity and MASH.    More details here: https://bit.ly/3NXwRUD 

Next week, we will provide a corporate update and publish our third quarter 2024 financial results. Learn more: https://bit.ly/3NUPSXU 

We are proud sponsors of this year’s MOSAIC – Global NASH/#MASH Trialist Forum in Washington, D.C.! Connect with us onsite to learn more about our efforts to develop impactful medicines for #MASH patients, and join our Chief Medical Officer, M. Scott Harris, M.D, and Vice President of Clinical Development, Sarah Browne, M.D., for various panels throughout the forum exploring a range of topics around #MASH.    Learn more: https://bit.ly/4gDoxql 

Tomorrow, our Vice President of Clinical Operations, Randy Brown, M.S., will be onsite at the 17th Clinical Trials Strategic Summit in San Francisco to discuss outsourcing strategies for small to midsize #biotech companies. Learn more: https://bit.ly/47JdjMR.   Agile Falcon Strategic Group LLC.  

We will be presenting data from our 12-week #clinicaltrial evaluating #pemvidutide in subjects with #MASLD at The Liver Meeting® hosted by the American Association for the Study of Liver Diseases (AASLD) that support pemvidutide’s potential benefit on #MASH and its associated co-morbidities. Learn more: https://lnkd.in/ehYn4KNv.   #TLM24 #GLP1 #Glucagon 

Our Vice President of Clinical Development, Sarah Browne, M.D., was recently featured in the October issue of The Medicine Maker!    Dr. Browne shares her insights and perspectives on the future of pharma and #biotech. Learn about her trend predictions about #obesity, personalized medicine and #clinicaltrials approaches in the latest publication: https://bit.ly/3BqamEH 

We are committed to improving metabolic health for patients and families everywhere. This #NationalLiverAwarenessMonth, we come together to share knowledge and advocate for the unmet needs of those living with #MASH.     Visit our partners at the Global Liver Institute, Fatty Liver Foundation and NASH kNOWledge for valuable resources on liver disease prevention & lifestyle tips. 

We are thrilled to share that our Chief Executive Officer, Dr. Vipin Garg, has been named to the 2024 PharmaVoice 100 list! This award recognizes the top 100 influential leaders in the #pharma and #biotech sectors for their innovation and impact. Join us in congratulating Dr. Garg for this prestigious recognition of his leadership and dedication to advancing innovative therapies for #obesity and #liver disease. See the full list here: https://lnkd.in/eAXkx4x8. #PV100 #PharmaVoice100

Next week, our Chief Executive Officer, Dr. Vipin Garg, and Chief Medical Officer, M. Scott Harris, will participate in a #firesidechat at the H.C. Wainwright 8th Annual #MASH Virtual Conference to discuss our mission to transform the therapeutic standard for #metabolicdiseases, starting with #pemvidutide, our #GLP1/#Glucagon dual receptor agonist for the treatment of #obesity and MASH. Learn more: https://bit.ly/3N64ymi    H.C. Wainwright & Co., LLC